Meibomian Gland Dysfunction Market Report 2026

Meibomian Gland Dysfunction Market Overview

• Meibomian Gland Dysfunction market size has reached to $4.42 billion in 2025 • Expected to grow to $6.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Prevalence Of Eye Diseases Drives The Growth Of The Market Due to Increasing Screen Time And Digital Eye Strain • Market Trend: Innovative Eye Drop Therapies Target Root Causes Of Tear Evaporation And Dry Eye Symptoms • North America was the largest region in 2025.

What Is Covered Under Meibomian Gland Dysfunction Market?

Meibomian gland dysfunction (MGD) is a common eye condition in which the meibomian glands, located in the eyelids, become blocked or produce an abnormal quality of oil. This disrupts the tear film, leading to symptoms such as dryness, irritation, inflammation, and blurry vision. MGD is a leading cause of dry eye disease and can range in severity from mild to severe. The main treatment types of meibomian gland dysfunction are medication, surgery, and lifestyle modifications. Medication refers to the use of drugs or other substances to treat, cure, prevent, or manage diseases, symptoms, or health conditions under medical supervision. Several dysfunctions include obstructive, evaporative, or mixed types based on dysfunction, and the severity of MGD ranges from mild to moderate to severe, with treatments distributed through channels such as hospitals, clinics, pharmacies, and online retailers. These solutions cater to end users, including hospitals, ophthalmology clinics, and home care settings.

What Is The Meibomian Gland Dysfunction Market Growth Forecast?

The meibomian gland dysfunction market size is expected to see strong growth in the next few years. It will grow to $6.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing adoption of device-assisted therapies, rising investments in ophthalmic care, growing awareness of chronic eye conditions, expansion of home-use treatment devices, increasing focus on personalized eye care. Major trends in the forecast period include increasing adoption of advanced diagnostic tools, rising use of device-based therapies, growing preference for combination treatment approaches, expansion of home-based management solutions, enhanced focus on early disease detection.

Global Meibomian Gland Dysfunction Market Segmentation

1) By Treatment Type: Medication, Surgery, Lifestyle Modifications 2) By Dysfunction Type: Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction 3) By Disease Severity: Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction 4) By Distribution channel: Hospitals And Clinics, Pharmacies, Online Retailers 5) By End-User: Hospitals, Ophthalmology Clinics, Home Care Settings Subsegments: 1) By Medication: Topical Antibiotics, Topical Steroids, Lubricating Eye Drops, Topical Cyclosporine, Omega-3 Supplements 2) By Surgery: Meibomian Gland Probing, Intense Pulsed Light (IPL) Therapy, Thermal Pulsation Treatment, BlephEx 3) By Lifestyle Modifications: Warm Compress Therapy, Lid Hygiene, Dietary Adjustments, Blinking Exercises

What Is The Driver Of The Meibomian Gland Dysfunction Market?

The rising cases of eye disease are expected to propel the growth of the meibomian gland dysfunction (MGD) market going forward. Eye disease refers to any condition or disorder that affects the eye or visual system, impairing its structure, function, or overall health. The rising cases of eye disease are due to increasing screen time and digital eye strain, which cause symptoms such as dryness, blurred vision, and long-term retinal damage from prolonged exposure to blue light. Meibomian gland dysfunction contributes to eye disease by disrupting the stability of the tear film, resulting in inflammation, dryness, and a higher risk of ocular surface disorders. For instance, in February 2025, according to the National Institutes of Health (NIH), a US-based government agency, the global prevalence of myopia is expected to rise to 36.59% by 2040 and 39.80% by 2050, with the total number of cases anticipated to surpass 740 million by 2050. Therefore, rising cases of eye disease are driving the growth of the meibomian gland dysfunction (MGD) market.

Key Players In The Global Meibomian Gland Dysfunction Market

Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd

Global Meibomian Gland Dysfunction Market Trends and Insights

Major companies operating in the meibomian gland dysfunction market are focusing on developing innovative treatments such as prescription eye drop solutions to reduce tear evaporation and relieve dry eye symptoms. Prescription eye drop solutions, such as anti-inflammatory or antibiotic drops, help manage meibomian gland dysfunction by reducing inflammation, unclogging gland blockages, and improving tear film stability. For instance, in May 2023, Bausch + Lomb Corporation, a Canada-based eye health company, introduced MIEBO (perfluorohexyloctane ophthalmic solution), a groundbreaking prescription eye drop developed for treating dry eye disease (DED). As the first and only prescription eye drop to directly address tear evaporation, the leading cause of DED, MIEBO forms a protective, long-lasting layer over the eye’s surface. Its innovative water-free formulation provides effective and lasting relief, particularly for patients with dry eye symptoms associated with Meibomian gland dysfunction.

What Are Latest Mergers And Acquisitions In The Meibomian Gland Dysfunction Market?

In July 2023, CS Pharmaceuticals Limited, a UK-based pharmaceutical company, acquired AxeroVision Inc. for an undisclosed amount. With this acquisition, CS Pharmaceuticals aims to strengthen its ophthalmology portfolio and accelerate the development of innovative treatments for meibomian gland dysfunction (MGD)-related dry eye disease, addressing a high unmet medical need. AxeroVision Inc. is a US-based biotech company that focuses on developing innovative treatments for meibomian gland dysfunction.

Regional Outlook

North America was the largest region in the meibomian gland dysfunction market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Meibomian Gland Dysfunction Market?

The meibomian gland dysfunction market consists of revenues earned by entities by providing services such as diagnostic services, customized dry eye management plans, and thermal pulsation treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The meibomian gland dysfunction market also includes sales of artificial tears and lubricating eye drops, omega-3 supplements, prescription medications, and intense pulsed light (IPL) therapy devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Meibomian Gland Dysfunction Market Report 2026?

The meibomian gland dysfunction market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the meibomian gland dysfunction industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.